The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia

Röder B, Fahnenstiel H, Schäfer S, Budeus B, Dampmann M, Eichhorn M, Angermüller S, Brost C, Winkler T, Seifert M, Nitschke L (2023)

Publication Type: Journal article

Publication year: 2023

Journal

DOI: 10.15252/embr.202256420

Abstract

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults in the Western world. B cell receptor (BCR) signaling is known to be crucial for the pathogenesis and maintenance of CLL cells which develop from mature CD5⁺ B cells. BCR signaling is regulated by the inhibitory co-receptor Siglec-G and Siglec-G-deficient mice have an enlarged CD5⁺ B1a cell population. Here, we determine how Siglec-G expression influences the severity of CLL. Our results show that Siglec-G deficiency leads to earlier onset and more severe course of the CLL-like disease in the murine Eμ-TCL1 model. In contrast, mice overexpressing Siglec-G on the B cell surface are almost completely protected from developing CLL-like disease. Furthermore, we observe a downmodulation of the human ortholog Siglec-10 from the surface of human CLL cells. These results demonstrate a critical role for Siglec-G in disease progression in mice, and suggest that a similar mechanism for Siglec-10 in human CLL may exist.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Essen Germany (DE)

How to cite

APA:

Röder, B., Fahnenstiel, H., Schäfer, S., Budeus, B., Dampmann, M., Eichhorn, M.,... Nitschke, L. (2023). The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia. EMBO Reports. https://doi.org/10.15252/embr.202256420

MLA:

Röder, Bettina, et al. "The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia." EMBO Reports (2023).

BibTeX: Download